首页> 美国卫生研究院文献>Wiley-Blackwell Online Open >Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized double-blind placebo-controlled trial

【2h】

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized double-blind placebo-controlled trial

机译：每日一次的GLP-1受体激动剂利西拉肽对二甲双胍控制不足的2型糖尿病患者的剂量依赖性作用：一项随机双盲安慰剂对照试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

AimsTo evaluate the dose–response relationship of lixisenatide (AVE0010), a glucagon-like peptide-1 (GLP-1) receptor agonist, in metformin-treated patients with Type 2 diabetes.

机译：目的在二甲双胍治疗的2型糖尿病患者中评估胰高血糖素样肽1（GLP-1）受体激动剂利西拉肽（AVE0010）的剂量反应关系。

著录项

期刊名称 Wiley-Blackwell Online Open
作者
R E Ratner; J Rosenstock; G Boka;
展开▼
作者单位

展开▼
年(卷),期 -1(27),9
年度 -1
页码 1024–1032
总页数 9
原文格式 PDF
正文语种
中图分类
关键词
glucagon-like peptide-1 receptor agonist glycaemic control lixisenatide Type 2 diabetes;

机译：胰高血糖素样肽-1受体激动剂;血糖控制;利西拉来;2型糖尿病;

相似文献

外文文献
中文文献
专利

1. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. [J] . Ratner RE, Rosenstock J, Boka G Diabetic medicine: A journal of the British Diabetic Association . 2010,第9期

机译：每天一次的GLP-1受体激动剂利西拉来对二甲双胍控制不充分的2型糖尿病患者的剂量依赖性作用：一项随机，双盲，安慰剂对照试验。
2. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia) [J] . SeinoY., MinK.W., NiemoellerE., Diabetes, obesity & metabolism . 2012,第10期

机译：每日一次的GLP-1受体激动剂利西拉来在亚洲2型糖尿病患者中接受或不接受磺脲类药物的基础胰岛素控制不足的随机，双盲，安慰剂对照试验（GetGoal-L-Asia）
3. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono) [J] . FonsecaV.A., Alvarado-RuizR., RaccahD., Diabetes care . 2012,第6期

机译：每日一次的GLP-1受体激动剂利西拉来单药治疗的有效性和安全性：一项针对2型糖尿病患者的随机，双盲，安慰剂对照试验（GetGoal-Mono）
4. MULTI-CENTER, PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED STUDY OF ORAL TOCERANIB PHOSPHATE (PALLADIATM, SU11654), A RECEPTOR TYROSINE KINASE INHIBITOR, FOR THE TREATMENT OF DOGS WITH RECURRENT MAS [C] . Cheryl L London, Carolyn J Henry, Anthony W Rusk, Annual conference of the Veterinary Cancer Society . 2008

机译：多中心，安慰剂对照，双盲，随机研究口服Toceranib磷酸盐（Palladia TM，SU11654），受体酪氨酸激酶抑制剂，用于治疗经常性MAS的狗
5. A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Fish Oil (Eicosapentaenoic Acid and Docosahexaenoic Acid) on Lung and Systemic Inflammation in Patients with Acute Lung Injury. [D] . Stapleton, Renee Doney. 2010

机译：鱼油（二十碳五烯酸和二十二碳六烯酸）对急性肺损伤患者的肺和全身炎症的II期，随机，双盲，安慰剂对照试验。
6. Randomized double-blind placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia) [O] . Y Seino, K W Min, E Niemoeller, -1

机译：每日一次的GLP-1受体激动剂利西拉来对亚洲2型糖尿病患者的基础胰岛素控制不足或不使用磺脲类药物的随机双盲安慰剂对照试验（GetGoal-L-Asia）
7. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial [O] . Ratner, R E, Rosenstock, J, Boka, G 2010

机译：每日一次的GLP-1受体激动剂利西拉肽对二甲双胍控制不充分的2型糖尿病患者的剂量依赖性作用：一项随机，双盲，安慰剂对照试验

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized double-blind placebo-controlled trial

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅